Targeting the cancer lesion, not the whole prostate
- PMID: 32676439
- PMCID: PMC7354301
- DOI: 10.21037/tau.2019.09.12
Targeting the cancer lesion, not the whole prostate
Abstract
Modern cancer treatment aims to conserve as much healthy tissue as possible. This has been challenging in the treatment of prostate cancer due to the difficulty in imaging the gland and concerns over leaving multifocal cancer untreated. With improvements in imaging and understanding of multifocal prostate cancer evidence now shows accurate treatment of just the primary focus of cancer or the index lesion can control progression or recurrence of the disease. Many different energy sources are now available to target the cancer lesion within the prostate with less significant side-effects on urinary and sexual function compared to radical treatment. Evidence shows that men value these functions highly and would even trade years of life in exchange for preserved retention of continence or erectile function. Focal treatment of prostate cancer aims to provide both cancer control and preservation of sexual and urinary functions so that men do not have to make a choice between the two. This is a treatment option that men clearly want and deserve.
Keywords: Prostate cancer; cryotherapy; focal brachytherapy; focal radiofrequency ablation (focal RFA); focal therapy; high-intensity focused ultrasound (HIFU); index lesion; irreversible electroporation (IRE); laser interstitial therapy (LITT); photodynamic therapy (PDT); vascular-targeted photodynamic therapy (VTP).
2020 Translational Andrology and Urology. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2019.09.12). The series “Prostate Imaging and Focal Therapy” was commissioned by the editorial office without any funding or sponsorship. HUA served as an unpaid Guest Editor of the series. DR is a clinical research fellow funded by a research grant from Prostate Cancer UK. HUA reports grants and personal fees from Sonacare, grants and personal fees from Boston Scientific, grants and personal fees from Sophiris Biocorp, grants from Trod medical, NB has no other conflicts of interest to declare.
Similar articles
-
New treatments for localized prostate cancer.Urology. 2008 Dec;72(6 Suppl):S36-43. doi: 10.1016/j.urology.2008.08.506. Urology. 2008. PMID: 19095127
-
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.Eur Urol. 2017 Jan;71(1):17-34. doi: 10.1016/j.eururo.2016.08.044. Epub 2016 Aug 29. Eur Urol. 2017. PMID: 27595377 Review.
-
Focal therapy for prostate cancer: Making the punishment fit the crime.Prog Urol. 2021 Dec;31(16):1080-1089. doi: 10.1016/j.purol.2021.08.037. Epub 2021 Sep 16. Prog Urol. 2021. PMID: 34538741 Review.
-
[FOCAL TREATMENT OF PROSTATE CANCER - LEADING AND FUTURE TECHNIQUES, OUTCOMES AND COMPLICATIONS].Harefuah. 2021 Sep;160(9):608-614. Harefuah. 2021. PMID: 34482675 Review. Hebrew.
-
Ablation energies for focal treatment of prostate cancer.World J Urol. 2019 Mar;37(3):409-418. doi: 10.1007/s00345-018-2364-x. Epub 2018 Jun 25. World J Urol. 2019. PMID: 29943219 Free PMC article. Review.
Cited by
-
Machine learning prediction of Gleason grade group upgrade between in-bore biopsy and radical prostatectomy pathology.Sci Rep. 2024 Mar 11;14(1):5849. doi: 10.1038/s41598-024-56415-5. Sci Rep. 2024. PMID: 38462645 Free PMC article.
-
One-year Follow-up Results of Transperineal Biopsy For Patients Undergoing Irreversible Electroporation Treatment in Localized Prostate Cancer.Urol Res Pract. 2023 Nov;49(6):381-386. doi: 10.5152/tud.2023.23150. Urol Res Pract. 2023. PMID: 37971388 Free PMC article.
-
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Front Oncol. 2022 Sep 23;12:980239. doi: 10.3389/fonc.2022.980239. eCollection 2022. Front Oncol. 2022. PMID: 36212416 Free PMC article. Review.
-
Higher pulse frequency of near-infrared laser irradiation increases penetration depth for novel biomedical applications.PLoS One. 2021 Jan 7;16(1):e0245350. doi: 10.1371/journal.pone.0245350. eCollection 2021. PLoS One. 2021. PMID: 33411831 Free PMC article.
-
Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies.Molecules. 2020 Nov 19;25(22):5417. doi: 10.3390/molecules25225417. Molecules. 2020. PMID: 33228126 Free PMC article. Review.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources